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Dysfunction of the mTOR pathway is a risk factor
for Alzheimer’s disease
Sharon C Yates1, Amen Zafar1, Paul Hubbard1, Sheila Nagy1, Sarah Durant2, Roy Bicknell2, Gordon Wilcock3,
Sharon Christie3, Margaret M Esiri4, A David Smith5 and Zsuzsanna Nagy1*
Abstract
Background: The development of disease-modifying therapies for Alzheimer’s disease is hampered by our lack of
understanding of the early pathogenic mechanisms and the lack of early biomarkers and risk factors.
We have documented the expression pattern of mTOR regulated genes in the frontal cortex of Alzheimer’s disease
patients. We have also examined the functional integrity of mTOR signaling in peripheral lymphocytes in
Alzheimer’s disease patients relative to healthy controls.
Results: In the brain mTOR is seen to control molecular functions related to cell cycle regulation, cell death and
several metabolic pathways. These downstream elements of the mTOR signaling cascade are deregulated in the
brain of Alzheimer’s disease patients well before the development of pathology. This dysregulation of the mTOR
downstream signaling cascade is not restricted to the brain but appears to be systemic and can be detected in
peripheral lymphocytes as a reduced Rapamycin response.
Conclusions: The dysfunction of the signaling pathways downstream of mTOR may represent a risk factor for
Alzheimer’s disease and is independent of the ApoE status of the patients.
We have also identified the molecular substrates of the beneficial effects of Rapamycin on the nervous system. We
believe that these results can further inform the development of clinical predictive tests for the risk of Alzheimer’s
disease in patients with mild cognitive impairment.
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Background
Late-onset Alzheimer’s disease (AD) has become the
silent epidemic of the 21st century and the effort to
understand the disease process and develop early diag-
nostic and therapeutic interventions has been enormous.
The failure to find effective drugs based on the amyloid
cascade hypothesis has prompted the recent re-
evaluation of the leading theory for the pathogenesis of
AD [1,2].
A more recent alternative hypothesis for the pathogen-
esis of AD involves the cell cycle. The hypothesis postu-
lates that AD is the consequence of aberrant re-entry of
neurones into the cell division cycle and subsequent
regulatory failure [3,4]. Whilst neurons were historically
thought to be terminally differentiated, there is now a
considerable body of evidence to indicate that neurons
in fact are able to re-enter the cell cycle (reviewed in
[3]). Whether cell cycle re-entry is part of the normal
life-cycle of a healthy neuron, or is restricted to diseased
neuronal states, remains unclear [3,5,6]. Nevertheless,
healthy neurons are not thought to pass the G1/S check-
point and do not replicate their DNA. The qualitative
jump from healthy ageing to Alzheimer’s disease appears
to be the neuronal commitment to DNA replication and
subsequent entry into the G2 phase (reviewed in [7]).
Although the involvement of the cell cycle in the patho-
genesis of AD explains many features of the disease
unsolved by previous hypotheses (reviewed in [3,6,7] it
also raises many questions. Most importantly, what are
the triggers and regulators of the cell division cycle that
drive the unsuccessful proliferation-attempt in neurons
and how do these relate to ApoE, the strongest genetic
risk factor for AD?
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The mammalian target of rapamycin (mTOR) is a
highly conserved serine-threonine kinase that is essential
for the co-ordination of intra and extra-cellular signals
concerning cell growth, division and differentiation [8].
It is found in two complexes within the cell: mTORC1
and mTORC2, which act upstream of the complex mTOR
pathway. MTORC1, responsible for co-ordinating growth
factor dependent growth and proliferation, is turned
on in response to various upstream signals such as
growth factors and nutrients (summarised in Figure 1)
and is inhibited by the naturally occurring macrolide
rapamycin [9].
In the nervous system the mTOR pathway is known to
play a key role in regulating synaptic remodelling and
long term potentiation (LTP) [10-12]. The overactivation
of the mTOR signalling pathway on the other hand has
been implicated in the formation of erroneous connec-
tions between neurons in epilepsy [13-15] and after
trauma [16,17]. Furthermore, the mTOR pathway plays
a key role in regulating autophagy in neurons: one of the
mechanisms by which cells turn over proteins and
organelles [12,18]. In recent years our understanding of
the role of mTOR in physiology and pathology of the
nervous system has dramatically increased. However,
we do not have a full inventory of the downstream
effectors of mTOR in the CNS and do not understand
how modifications in mTOR activity contribute to
neurodegeneration [19].
The first evidence to indicate that mTOR signalling is
altered in AD was our finding of a reduced Rapamycin
response in AD patients relative to healthy controls [20].
Later, the alteration in mTOR signalling in lymphocytes
were found to be associated with cognitive decline in
AD [21] and the reduced responsiveness to Rapamycin
was attributed to conformational changes in p53 [22].
A number of studies have since shown an up-regulation
of various components of the mTOR pathway, down-
stream of mTORC1, in the brain of AD patients [23-25].
There is an association between the presence of these acti-
vated components and the accumulation of phospho-tau
(p-tau) and neurofibrillary tangles (NFT) in neurons
[23-25]. It was concluded that the mTOR pathway medi-
ates tau phosphorylation [26,27], the first step in the pro-
duction of the intracellular NFT associated with AD.
There is also evidence of an association between mTOR
signalling and beta-amyloid, although the nature of the
association is uncertain [18,28,29]. Rapamycin induced
inhibition of mTORC1 has also been shown to decrease
beta-amyloid expression by increasing the rate of autoph-
agy [18,29]. As MTORC1 is a negative regulator of
autophagy, the increased mTOR signalling associated with
AD may reduce the rate of autophagy, potentially leading
Figure 1 A simplified version of the mTOR signalling pathway. MTORC1 receives and integrates the signals from various upstream pathways,
including pathways triggered by nutrients, growth factors, hypoxia and insulin that promote cell growth, division and differentiation. Rapamycin
is a powerful inhibitor of mTORC1 activity. Abbreviations: 4E-binding protein (4EBP1); eukaryotic translation initiation factor 4E (eIF4E); Receptor
Tyrosine Kinase (RTK); Insulin receptor (INSR); Protein Kinase C (PKC); Extracellular Signal Regulated Kinase (ERK); (Ras); Protein kinase B (AKT).
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to an accumulation of the hallmarks of AD, secondary to
reduced clearing. More recently in animal models
Rapamycin has been found to be a good candidate for the
treatment of AD [29].
The aims of this study were to identify the Rapamycin-
regulated genes that are differentially expressed in
Alzheimer’s disease brain and to evaluate the usefulness of
the Rapamycin test in lymphocytes as a risk factor for
Alzheimer’s disease.
Methods
Peripheral blood from healthy controls, used to stand-
ardise and determine the analytical performance of the
Rapamycin assay, was provided by the NHS blood and
transfusion centre (ethical approval no: 07/Q2707/97).
Blood from this source was also used for the determin-
ation of rapamycin-regulated genes in lymphocytes by
gene expression microarray.
Peripheral blood from elderly subjects was provided by
the Oxford Project to Investigate Memory and Ageing
(OPTIMA) (ethical approval no: 09/H0107/9 and 18/07/
2007). The samples provided were from Alzheimer
patients (n=51, age range=57-92, mean age=79) who
fulfilled the NINCDS-ARDRA criteria for probable AD
[30] or patients with mild cognitive impairment (MCI,
n=27, age=69-95, mean age=83) fulfilling the Petersen
criteria [31]. Additional samples were collected from
healthy age matched controls (n=68, age range=60-94,
mean age=79.5). Appropriate consent and ethical
approval was sought prior to the start of the study.
Frozen post-mortem brain tissue (frontal lobe) of
41 AD sufferers (Braak stage III-IV: n=19; Braak stage
V-VI: n=22) and 5 elderly controls was provided by
the Thomas Willis brain bank (ethical approval no:
07/Q2707/98). The included patients had no other
pathology than AD that was thought to contribute to
the severity of dementia, and had plasma homocyst-
eine levels below 35 μM prior to death. The severity
of AD was classified on the basis of the Braak staging
[32]. For the sake of simplicity we use the termin-
ology of ‘limbic stage AD’ for patients in Braak stages
III-IV and ‘neocortical stage AD’ for patients in Braak
stage V-VI, as proposed by Braak [32]. Patient selec-
tion was guided by quantitative assessment of the
AT8-positive phospho tau, DC11-positive tau and
beta-amyloid (performed previously) (Additional file 1:
Figure S1, Figure S2 and Figure S3) to ensure that the
groups selected were homogenous in terms of pathology
and that limbic stage patients did not have significant
amyloid deposition in the brain region studied relative
to controls. The number of cases included in the study
was based on availability, not statistical power calcula-
tions. Additional details on patient data can be found in
Additional file 2: Table S1.
Lymphocyte separation and cell culture
Peripheral blood was collected in Heparin vacutainers
and shipped at room temperature. The separation of
lymphocytes was carried out within 24 hours of blood
collection using established protocols (Lymphoprep,
Axis-Shield, NYC-1114545). The separated and washed
lymphocytes were re-suspended in 9:1 FCS: DMSO and
stored at −70°C (at least 24 hours) before placing into
liquid nitrogen.
Frozen lymphocytes were thawed in batches and
washed in RPMI-1640 to remove freezing medium. The
cells were then cultured (1million/ml density) in RPMI-
1640 medium supplemented with L-glutamine (2%),
Penicillin/Streptomicin (1%), PHA (2.5% of PAA PHA)
and FCS (15%) for 48 hours. From each patient two sets
of identical cultures were set up in 96 well plates (6 wells
in each set). Following the initial 48 hours culture half of
the cultures from each set were treated with Rapamycin
(100 ng/ml) while half were treated with DMSO alone
(solvent for Rapamycin) for a further 24 hours. At the
end of the treatment period (total 72 hours in culture)
one set of cultures was collected for LDH assay by freez-
ing the samples at -20°C. The second set of cultures was
fixed with ice-cold 85% ethanol and stored at 4°C for
flow cytometry.
Assessment of cell numbers and cell cycle kinetics in
cultured lymphocytes
Overall cell numbers were determined using a commer-
cially available kit (CytoTox 96 non-radioactive Cytotoxicity
Assay, Promega) that quantitatively measures lactate
dehydrogenase (LDH) release upon cell lysis [33]. LDH
positive control was used to generate a calibration
curve. Lymphocytes were lysed by freezing at −20°C for
at least overnight. Samples were thawed and kept at
4°C before use. 30 μl of culture was distributed into 96
well plates; each sample was represented in triplicates.
50 μl of ice-cold reconstituted substrate buffer was
added to each well. Plates were incubated at room
temperature and protected from light. Reaction was
stopped with 50 μl of stop solution and absorbance
read at 490 nm. Cell numbers are directly proportional
to the absorbance values which represent LDH activity.
The quality standards for the LDH assay are included
in the supplementary methods (Additional file 3).
From each culture the LDH assay was carried out in
triplicate (while each culture condition was repeated in
three technical replicates as well). The coefficient of
variance (CV) of the LDH carried out from the same
culture sample was consistently <10%, while the CV
from the triplicate cultures was also <10%. The assay
generated three variables for each patient: cell numbers
at the time of culture seeding and the cell numbers after
three days in culture with and without Rapamycin.
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Cell cycle analysis was carried out to analyse the effect
of cell cycle inhibitor drugs on the cell cycle kinetics of
lymphocytes. The assessment relies on the measurement
of Propidium iodide (PI) incorporation into DNA. The
fixed lymphocytes were washed with ice cold PBS and
stained with propidium iodide (PI 20 μg/ml; RNAs A
100 20 μg/ml and 0.1% Triton X in PBS) for minimum
30 minutes at room temperature. Cytometry was car-
ried out with a BD FacsCalibur cytometer fitted with a
96 well High Throughput Sampler. Quality standards
are included in the supplementary methods (Additional
file 3). The cytometry allowed the recording of cell frac-
tions in different phases of the cell cycle [34], apoptotic
fraction and non-dividing fraction of the cell popula-
tions both in control and Rapamycin treated cultures
from each patient.
Using the variables recorded from the first 47 control
subjects and 27 AD patients we performed logistic re-
gression to identify the variables that best predicted pa-
tient diagnosis. The identified variables were then used
to calculate the probability of AD in any given patient
(probability of AD based on Ly test). This probability
value then was analysed using ROC curve analysis to de-
termine the specificity and sensitivity of the assay as well
as the positive likelihood ratio at any given test results.
The same calculation was then applied to the subse-
quent 21 controls and 24 AD patients to check assay
performance in an independent patient group.
The probability of a patient having AD just based on
age was regarded as the pre-test probability of a patient
having AD. Published likelihood ratios were used to cal-
culate the post-test probability after an ApoE genotype
determination. The likelihood ratio obtained for any
given lymphocyte-test result (from the ROC curve) was
used to calculate the post-test probability of AD based
on the lymphocyte test. The comparison of pre-test and
post test probabilities in our patients was used as a
measure of improvement in the diagnostic prediction
achieved by the use of the lymphocyte test.
RNA extraction for microarray
To identify the genes regulated by the mTOR pathway
lymphocytes from young healthy donors were cultured
with and without rapamycin. The expected rapamycin
response was a reduction in cell proliferation and accu-
mulation of cells in the G1 phase relative to non-treated
cultures from the same individual. Lymphocytes were
cultured as described above. Total RNA was extracted
with TRI-reagent (Sigma) according to the standard
protocol and treated with DNase (Qiagen). Total RNA
was also extracted from the post mortem brain tissue as
described above.
The quality of the RNA was assessed on the Agilent 2100
Bioanalyser (see Additional file 3). Agilent microarrays were
used for expression analysis in order to minimise the
effect of RNA quality on the results [35-38] (see
Additional file 3).
Microarray
Two-colour microarray based gene expression analysis
(Agilent Technologies) was used to identify genes that
were differentially expressed in rapamycin-treated lym-
phocytes compared to untreated lymphocytes following
the standard protocol (Agilent manual: G4140-90050).
Briefly, 200 ng of RNA was amplified by conversion to
cDNA, and subsequently to labelled cRNA, with the
Low-Input Quick Amplification Labelling kit (Agilent
Technologies). Samples from rapamycin-treated lympho-
cytes and untreated lymphocytes were labelled with
Cyanine-3 and Cyanine-5 respectively. Labelled cRNA
was purified with the RNeasy mini column (Qiagen) and
quantified with a nanodrop Spectrophotometer. The two
samples were mixed (825 ng each), fragmented, and
hybridised to the 4x44K Agilent Whole Human Genome
Microarray at 65°C for 17 hours. The microarrays were
washed and scanned with the Agilent C Scanner on the
AgilentHD_GX_2color setting.
8×15 K Custom microarrays (Agilent Technologies)
were designed to include the identified 1127 rapamycin-
regulated genes in lymphocytes and 38 known rapamycin-
regulated genes based on an IPA Ingenuity search (www.
ingenuity.com) (total 1165 genes). Various housekeeping
genes (719 probes) and internal controls (3141 probes)
were also included. One-colour microarray based gene
expression analysis (Agilent Technologies) was used to
identify rapamycin-regulated genes that were differentially
expressed in brain affected by AD compared to control.
The one-colour microarray protocol is described in
manual: G4140-90040. Briefly, 200 ng of RNA per sub-
ject was converted to Cyanine-3 labelled cRNA with
the Low Input Quick Amplification Labelling kit
(Agilent Technologies). After purification and quantifi-
cation as described previously, 600ng of cRNA per sub-
ject was fragmented and hybridised to an 8×15 K
Custom microarray. The microarrays were scanned on
programme AgilentHD_GX_1color.
Microarray data analysis
The feature extraction programme was used to collate
the Microarray layouts with the output of the scanner.
The output from the 4×44 K Whole Human Genome
microarrays were processed to identify rapamycin-
regulated genes in lymphocytes; whereas the output of
the 8×15 K custom microarrays were processed to deter-
mine the expression level of the rapamycin-regulated
genes in the frontal lobe of each subject. The custom
microarray outputs were grouped according to AD se-
verity [32]. Statistical analysis of gene expression was
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carried out only for the 1165 rapamycin-regulated genes.
We used the ‘Statistical analysis of microarray’ software
(SAM) to carry out unpaired, two sample T-tests for
each gene in a group-of-interest compared to control.
Genes with an estimated false discovery rate (FDR)
<10% were considered differentially expressed. SAM was
carried out with 1000 permutations and the output
processed to remove duplicates. The functional analysis
of the genes differentially regulated was carried out with
IPA Ingenuity. Cluster and TreeView programs were
used for the analysis and visualization of the microarray
results [39].
The validation of the Microarray results was carried
out by Q-PCR for six genes (see Additional file 3 and
Additional file 2: Table S2.).
Results
Rapamycin-regulated genes in normal lymphocytes
associated with G1 inhibition
Two-colour Agilent gene expression array analysis iden-
tified 1127 genes whose expression was regulated by
rapamycin in lymphocytes (FDR<10%). Of the 1127
genes, 1033 were up-regulated and 94 genes down-
regulated in response to rapamycin.
The up- and down- regulated mTOR genes were
shown to be significantly enriched for 25 molecular and
cellular functions (Figure 2 and Figure 3), which
included cellular growth and proliferation, cell cycle, cell
morphology, free radical scavenging, and major meta-
bolic pathways (metabolism of nucleic acids, drugs,
vitamins and minerals, lipids, amino acids and carbohy-
drates – gene lists in Additional file 2: Tables S3 and S4).
See the supplementary material for associated diseases,
physiological systems and networks (Additional file 2:
Tables S5-S10).
In order to identify the Rapamycin-sensitive genes
whose regulation may be affected by the ApoE genotype
we have compared the list of 1165 mTOR regulated
genes (1127 identified by us and 38 identified from the
literature) with the list of 154 genes regulated in an
ApoE allele-specific manner (Additional file 2: Table S4
of reference [40]). We found only 6 overlapping genes
(A2M, B2M, GSN, LRP1, DDIT4 and MAL) in the two
datasets. Of these, only one gene (MAL) was found to
the differentially regulated in the hippocampus of AD
patient relative to controls in the original analysis [40].
Altered rapamycin-response elements in AD brain
The expression of Rapamycin regulated genes in the
brain was assessed using Agilent Custom arrays followed
by Significance Analysis of Microarrays (SAM) analysis
of the 1165 identified rapamycin-regulated genes only.
The comparison of gene expression in ApoE4 carriers
to non-carriers within the same Braak stages (separate
two-class unpaired analysis for limbic and neocortical
stage AD patients) confirmed that the ApoE genotype
had no effect on the expression of the rapamycin-
regulated genes in AD patients (data not shown). There-
fore all further analysis of limbic stage and neocortical
Figure 2 Molecular and cellular functions associated with genes up-regulated in lymphocytes in response to rapamycin treatment. The
chart shows the number of genes, expressed as a percentage of the total number, involved in each of the molecular and cellular functions
deemed significant by IPA Ingenuity.
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stage patients were carried out on all patients in these
groups irrespective of their ApoE genotype.
Altered rapamycin response elements in mild AD (limbic
stage) compared to control
Of the 1165 known rapamycin-regulated genes, SAM iden-
tified 112 (9.6%) that were differentially expressed in brain
affected by limbic stage AD compared to control (all up-
regulated). These were found to be significantly associated
with 20 molecular and cellular functions, such as cell cycle,
cell death, cellular movement, molecular transport, small
molecule biochemistry, vitamin and mineral metabolism
and cellular compromise (Figure 4, gene list in Additional
file 2: Table S11). Associated diseases, physiological
Figure 3 Molecular and cellular functions associated with genes down-regulated in lymphocytes in response to rapamycin treatment.
The chart shows the number of genes, expressed as a percentage of the total number, involved in each of the molecular and cellular functions
deemed significant by IPA Ingenuity.
Figure 4 Molecular and cellular functions associated with mTOR-regulated genes differentially expressed in the frontal lobe of mild AD
patients. Molecular and cellular functions associated with genes differentially expressed in the frontal lobe of mild AD patients (limbic stage)
compared to controls (112 genes). The chart shows the number of genes, expressed as a percentage of the total number, involved in each of the
molecular and cellular functions deemed significant by IPA Ingenuity.
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systems, networks and pathways are outlined in the supple-
mentary material (Additional file 2: Tables S12-S15).
Altered rapamycin response elements in advanced AD
(neocortical stage) compared to control
SAM identified 176 (15.1%) of the 1165 known rapamycin-
regulated genes as differentially expressed in brain affected
by advanced AD compared to control. The genes were sig-
nificantly enriched for involvement in 23 molecular and
cellular functions, which included cellular function and
maintenance, cellular movement, cellular growth and pro-
liferation, cell cycle, cell morphology, and various metabolic
pathways (Figure 5 and gene list in Additional file 2: Table
S16). Associated diseases and disorders, physiological sys-
tems, networks and pathways can be found in the supple-
mentary material (Additional file 2: Tables S17-S20).
Of the 176 genes identified 8 were included in the ana-
lysis based on their known association with the mTOR
pathway (IPA), while 168 of these genes were identified by
us as downstream effectors of mTOR. The differential ex-
pression of the majority of these genes (127/168, 76%) was
consistent with mTOR inhibition (identical to the direction
of change elicited by Rapamycin in lymphocytes, data not
shown).
Altered rapamycin response elements in AD compared to
control (multiclass analysis)
Of the 1165 rapamycin-regulated genes, multiclass ana-
lysis with SAM identified 55 genes that were differentially
expressed as a result of AD, irrespective of severity. The
differentially regulated genes were significantly enriched
for involvement in 24 molecular and cellular functions,
which included cellular development, cell death, cell cycle,
cell morphology, cellular growth and proliferation, and
metabolic pathways (Figure 6 and gene list in Additional
file 2: Table S21). Associated diseases, physiological sys-
tems, networks and pathways can be found in the supple-
mentary material (Additional file 2: Tables S22-S25).
The expression level of the 55 mTOR genes in the frontal
lobe were clustered by array and gene, with complete hier-
archical clustering, and visualised in a heat map (Figure 7).
Thirty-three of these genes were significantly up-regulated
in both early and advanced AD compared to control (all
these genes were also identified by the earlier two class un-
paired analysis). However, this analysis identified, relative to
the two-class unpaired analysis, an additional 22 genes that
were significantly down-regulated in mild AD compared to
control and remained down-regulated in advanced AD. For
the majority of subjects, the expression of this set of 55
rapamycin-regulated genes is altered early in the disease
process and remains altered in later stages. The arrays (pa-
tients) are clustered in a distinctive pattern: with the five
control subjects clustered to the left together with 9 limbic
stage and 6 neocortical stage patients and the rest of the
limbic (10) and neocortical (16) stage patients clustered to
the right.
Further comparison of the genes differentially expressed
in mild (limbic) and late (neocortical) AD (as determined
Figure 5 Molecular and cellular functions associated with mTOR-regulated genes differentially expressed in the frontal lobe of
advanced AD patients. Molecular and cellular functions associated with genes differentially expressed in the frontal lobe of advanced AD
patients (neocortical stage) compared to controls (176 genes). The chart shows the number of genes, expressed as a percentage of the total
number, involved in each of the molecular and cellular functions deemed significant by IPA Ingenuity.
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by separate two-class unpaired analyses in SAM) indicates
that a further 63 of the 1165 rapamycin-regulated genes
were shown to be differentially regulated in both mild and
advanced AD compared to controls. However, the expres-
sion of these genes showed a relatively wide variation from
patient to patient (see cluster analysis visualised in
Figure 8).
We also found that 98 Rapamycin-regulated genes were
differentially expressed in either mild AD (17 genes) or
advanced AD (81 genes) only (Figure 9) identifying three
distinct patient clusters.
Comparison of differentially expressed transcripts with
known AD-related genes
The IPA Ingenuity knowledge database contains informa-
tion about established gene associations with disease that
have been derived from peer-reviewed journals and other
high quality sources. Only verified gene and disease asso-
ciations are included in the database (associations based
on genetics and expression).
IPA Ingenuity identifies 519 genes that are known to be
involved in AD. This gene list was compared to the list of
genes we found to be regulated by rapamycin (1165
genes, ~ 5.82% of the whole genome). Of the 519 AD-
related genes we found that 44 (8.48%) were also identified
as downstream molecules of mTOR (Additional file 2:
Table S26). Additionally while so far 519 genes of the
whole genome were found to be associated with AD
(2.59% of the whole genome), we have found that 176 of
the 1165 mTOR regulated genes (15.1%) have altered
expression in AD indicating that the mTOR pathway has
a significant involvement in AD (Chi-square=402.354,
p < 0.0001).
Rapamycin response in lymphocytes from Alzheimer’s
disease patients
The proliferation rate and population doubling time of
lymphocyte cultures with and without rapamycin treat-
ment was calculated from the cell number estimates de-
rived from the LDH assay. We found that the baseline
proliferation characteristics (population doubling time,
PDT, without Rapamycin treatment) were independent
of the age of the patients in our cohort (p=0.162,
R2=1.9892%; Additional file 1: Figure S5).
To assess the relative response to Rapamycin in lym-
phocytes we have calculated the PDT as well as the
length of the G1 time in lymphocyte cultures with and
without rapamycin for each patient. The relative
rapamycin response in lymphocytes (lengthening of the
proliferation and G1 time) showed that AD patients
have a significantly poorer response to Rapamycin
than healthy elderly control subjects (Additional file 1:
Figure S6 and Fig. S7). We have also found that the
rapamycin response in lymphocytes was not ApoE
dependent (Additional file 1: Figure S8 and Figure S9).
Figure 6 Molecular and cellular functions associated with genes differentially expressed in AD brain irrespective of severity (55 genes).
The chart shows the number of genes, expressed as a percentage of the total number, involved in each of the molecular and cellular functions
deemed significant by IPA Ingenuity.
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Logistic regression analysis indicates that the combin-
ation of the baseline proliferation characteristics and the
relative change induced by Rapamycin in the lympho-
cytes was strongly predictive of the clinical diagnosis in
the first 74 patients (27 probable AD and 47 Controls)
(P < 0.0001, OR=3.96, and predicted area under the
ROC curve: AUC=86.1%, 95% CI: 0.760 to 0.930). ROC
analysis of the predicted probability (calculated from the
logistic regression) was capable of distinguishing control
subjects from AD patients with 88.3% accuracy
(AUC=0.88, 95% CI: 0.788 to 0.946; p<0.0001). The spe-
cificity and sensitivity of the prediction (at the >0.5 cut-
off ) is 81.48% and 87.23% respectively (Figure 10a).
The inclusion of the ApoE4 status of the patient in the
predictive algorithm increased the overall accuracy of
the test (AU ROC: 91.3%, 95% CI: 0.824-0.966,
p<0.0001). The sensitivity of the combined test increases
to 85% at the expense of the specificity which decreases
to 82.9% (Figure 10b).
In the second independent patient group (21 control
and 24 AD patients) the application of the test and prob-
ability calculations indicates that at the same cut-off
value the lymphocyte response to Rapamycin alone iden-
tifies 78.6% of the patients accurately with a 87.5% speci-
ficity and 76.2% sensitivity. Using ApoE status as a
co-predictor the specificity of the prediction increases to
Figure 7 Differentially expressed mTOR genes in the frontal lobe of AD patients. Heat map of differentially expressed mTOR genes in the
frontal lobe of AD patients compared to control. Differential expression was determined by multiclass analysis in SAM, with the subjects split into
three groups according to Braak staging: control, mild AD (limbic stage) and advanced AD (neocortical stage). The cut-off point for differential
expression was <10% FDR. The heat map was generated with Cluster and Treeview, with complete hierarchical clustering by gene and array. The
expression level of each gene relative to the median expression of the gene across all samples is represented on a red-green colour scale. The
colours represent the log ratio of gene expression in an individual patient. Downregulated genes are represented in green (saturated green: log
ratios −3.0 and below) while upregulated genes are represented in red (saturated red: log ratios 3.0 and above). Cells with log ratios of 0 (gene
expression unchanged) are black. The arrays are identified by the patient codes that are described in Additional file 2: Table S1 (C: Control,
L: Limbic stage AD, N: Neocortical stage AD) while the genes are identified by the gene name.
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95.83% at the expense of the sensitivity which decreases
to 66.67%.
ROC analysis indicates that the ApoE4 status, similar
to previous studies, is predictive of the patient’s diagno-
sis (AUC: 0.735; 95% CI: 0.646-0.812). The comparison
of ROC curves, however, indicates that the lymphocyte
Rapamycin-response provides a significantly better pre-
diction of AD risk (Figure 11).
Overall the lymphocyte test is negative in 85.6% of
controls and positive in 86.2% of AD patients (sensitivity
and specificity 86% and 82% respectively), indicating that
a positive test result is associated with a significantly
increased risk of developing AD (OR: 28.80, 95% CI:
10.46 to 79.33; p< 0.0001).
As the age of the subjects included varied between 57
to 95 years, based on published demographic data, the
Figure 8 Rapamycin-regulated genes differentially expressed in both mild and advanced AD. Heat map of the 65 rapamycin-regulated
genes that were shown to be differentially expressed in both mild and advanced AD compared to control, in separate two-class unpaired SAM
analyses. The cut-off point for differential expression was <10% FDR. The heat map was generated with Cluster and Treeview, with complete
hierarchical clustering by gene and array. The expression level of each gene relative to the median expression of the gene across all samples is
represented on a red-green colour scale. The colours represent the log ratio of gene expression in an individual patient. Downregulated genes
are represented in green (saturated green: log ratios −3.0 and below) while upregulated genes are represented in red (saturated red: log ratios
3.0 and above). Cells with log ratios of 0 (gene expression unchanged) are black. The arrays are identified by the patient codes that are described
in Additional file 2: Table S1 (C: Control, L: Limbic stage AD, N: Neocortical stage AD) while the genes are identified by the gene name.
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Figure 9 Differentially expressed mTOR-related genes in either mild or advanced AD. Heat map visualising the expression level of the 98
genes that were either differentially expressed in mild AD (17 genes) or in advanced AD (81 genes) only. The cut-off point for differential
expression was <10% FDR. The heat map was generated with Cluster and Treeview, with complete hierarchical clustering by gene and array. The
expression level of each gene relative to the median expression of the gene across all samples is represented on a red-green colour scale. The
colours represent the log ratio of gene expression in an individual patient. Downregulated genes are represented in green (saturated green: log
ratios −3.0 and below) while upregulated genes are represented in red (saturated red: log ratios 3.0 and above). Cells with log ratios of 0 (gene
expression unchanged) are black. The arrays are identified by the patient codes that are described in Additional file 2: Table S1 (C: Control, L:
Limbic stage AD, N: Neocortical stage AD) while the genes are identified by the gene name.
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age-dependent probability of AD (pre-test probability)
varied from 2.3% to 40.5%. Using only the ApoE4 status
as a risk factor the post-test probability of AD has risen to
above 80% in 13% (9/67) control subjects, 22.7% (5/27)
MCI and 54.9% (28/51) AD patients. Using the lympho-
cyte test alone the post-test probability has risen to above
80% in 17.9% (12/67) controls, 11% (3/27) MCI and 86.3%
(44/51) AD patients. When the ApoE4 status and
lymphocyte test were used together the post-test probabil-
ity of AD has risen above 80% in 28% (19/67) of controls,
29.6% (8/27) MCI and 92.2% (47/51) AD patients.
Discussion
The functional significance of the mTOR pathway has been
revealed by functional studies using Rapamycin as an
mTOR inhibitor. However, the downstream effectors of the
pathway have not been fully mapped [19]. Our expression
analysis in lymphocytes has now identified genes that are
downstream effectors of mTOR. The downregulation of
genes involved in antigen presentation, cell-to-cell signal-
ling (mainly involved in the immune response), and cellular
growth and development are consistent with previous stud-
ies into the mechanism of action of Rapamycin [41]. The
significantly larger number of genes upregulated by
Rapamycin (91%, 1033 of 1127 all Rapamycin-sensitive
genes) was somewhat unexpected. The analysis of func-
tional groups indicates that Rapamycin has a significant ef-
fect on genes involved in neuronal development and
function. Most of the neuronal functions associated with
these genes were already known to be affected by
Rapamycin [10,19], providing further validation of our re-
sults. We have now identified the downstream effectors of
the mTOR signalling pathway that are most likely the mo-
lecular substrates of the mTOR effect on neuronal plasticity
and LTP [10-12]. The strong effect of Rapamycin on these
cellular functions also identifies mechanisms responsible
for the beneficial effect of the drug in the transgenic model
of AD [29].
We have chosen the frontal lobe for differential gene ex-
pression studies because of the relatively late involvement
of this brain region in the disease process [32]. The sam-
ples from limbic stage patients included in the study had
minimal tau and amyloid pathology similar to that seen in
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Figure 10 ROC curve analysis of the performance of the lymphocyte test. a). Receiver operating characteristic (ROC) curve of the
lymphocyte test for differentiation between Alzheimer’s disease patients (probable AD, NINCDS-ARDRA criteria) and healthy control individual.
b). Receiver operating characteristic (ROC) curve of the combination of the lymphocyte test and ApoE4 status for differentiation between
Alzheimer’s disease patients (probable AD, NINCDS-ARDRA criteria) and healthy control individual.
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Figure 11 Comparison of ROC curves. ROC curve comparison.
Green curve: probability of AD due to age; Blue curve: probability of
AD based on ApoE4 status; Red line: probability of AD predicted by
the Rapamycin response in lymphocytes; Black line: probability of
AD as predicted by the combination of the Rapamycin response
and ApoE4 status.
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healthy controls (Additional file 1: Figure S1, Figure S2
and Figure S3). In contrast samples from neocortical stage
patients had significantly increased pathology. Thus gene
expression changes observed in limbic stage patients (rela-
tive to controls) represent the gene expression alterations
that precede the development of the AD-type pathology,
while changes in the neocortical stage samples represent
those that are associated with fully developed AD. While
ApoE genotype has a significant effect on gene expression
in the brain [40,42], it does not affect the expression of
the Rapamycin regulated genes. It is important to note
that the gene expression alterations in the brain are not
simply a consequence of mTOR activation [24,25]. Due to
RNA degradation the arrays from post-mortem samples
are likely to give false negative results affecting primarily
short transcripts, but with the Agilent microarrays the
possibility of false positive results is not greater than for
any other array technologies.
The differential expression of a large number of mTOR-
dependent genes in both the limbic (112/1165, 9.6%) and
neocortical stage AD (176/1165, 15.1 %) indicates that the
disruption of these molecular pathways is not merely a con-
sequence of the pathology and implies that the
dysregulation of the downstream pathways of mTOR may
play an important and early role in the development of AD.
It is also interesting that the differentially regulated genes in
limbic stage AD (112 genes) and neocortical stage AD (176
genes) were involved in very similar functional categories.
For the majority of the functional groups, the number of
mTOR genes affected in each category was greater in neo-
cortical stage than in limbic stage AD. Thus it appears that
the disruption of these pathways is present before AD path-
ology develops and the accumulating AD pathology only
worsens the dysfunction of the same pathways. The mo-
lecular pathways and functions we have found affected in
AD are largely the same as those identified earlier in brain
regions severely affected by the disease [40,42-45] or those
found to be altered in parallel with increased beta amyloid
load in the brain [46], with the significant difference that
we have now provided evidence that these pathways are
affected well before the pathology develops.
Since Rapamycin significantly affects the expression of
several genes associated with cell cycle control, prolifera-
tion and cell death in lymphocytes, it is not unexpected
that a simple cell proliferation assay combined with flow
cytometry is sufficient to assess the Rapamycin-response
Figure 12 Causes and consequences of mTOR activation in the brain. Vascular disease, diabetes, elevated plasma homocysteine levels,
trauma and ageing (all risk factor for AD) can elicit the various extracellular signals that can activate mTORC1. Normally, the activation of
downstream signals would ensure cell survival and damage repair. However, the dysfunction of the downstream effector pathways, du to genetic
variation, will lead to aberrant responses to mTOR activation in the brain, leading to AD-type pathology, neuronal death and glial activation.
Abbreviations: Homocysteine (Hcy); Receptor Tyrosine Kinase (RTK); Insulin receptor (INSR); Protein Kinase C (PKC); Extracellular Signal Regulated
Kinase (ERK); (Ras); Protein kinase B (AKT); Neurofibrillary tangle (NFT; Amyloid Precursor Protein (APP).
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from these cells in individual patients [20]. The strong as-
sociation between the outcome of the Rapamycin test in
lymphocytes and patient diagnosis indicates that the
d1ysfunction of the mTOR downstream signalling path-
way is affected systemically in AD patients, rather than
just in the brain. Thus, the dysfunction of the mTOR
pathway is most likely to be a constitutional characteristic
of an individual. As the genes involved in the downstream
signalling of mTOR are highly polymorphic in humans, it
is likely that this ‘constitutional’ dysfunction of the mTOR
pathway in different individuals depends on different
SNPs. Depending on the combinations of polymorphisms
present in individual patients, differential activation of
pathways downstream of mTOR may produce a variety of
functional outcomes in the brain in response to mTOR
activation. This increases the vulnerability of the brain to
the effects of ageing, hypoxia, trauma, elevated homocyst-
eine and diabetes, all known risk factors for AD
(summarised in Figure 12). Furthermore, the dysfunction
of this pathway could affect the efficacy of neuroprotective
therapies in these individuals.
A significant outcome of this study is that, although the
pathways affected in early and late AD are identical, the ex-
pression of the individual genes that make up these path-
ways is highly variable in the brain of different patients.
This suggests that it is the disruption of specific functional
pathways that is associated with AD rather than alterations
in a specific gene. This could explain the lack of finding of
a single genetic risk factor (other than ApoE) for late onset
Alzheimer’s disease [47].
We hypothesise that the assessment of the functional in-
tegrity of the downstream signalling cascade of mTOR
from lymphocytes allows assessment of the susceptibility of
that individual to develop AD rather than provide an as-
sessment of disease state. As such the dysfunction of the
mTOR pathway, as measured from lymphocytes, may rep-
resent a risk factor for the development of AD that could
be exploited diagnostically.
Both the alterations of the mTOR signalling cascade in
AD brain and the outcome of the lymphocyte test were in-
dependent of the ApoE status of the patients. These find-
ings support the hypothesis that the dysfunction of the
mTOR downstream signalling pathway, as a risk factor, is
independent of the ApoE genotype.
Further longitudinal studies in MCI patients are neces-
sary to demonstrate the clinical utility of the lymphocyte
test in the risk prediction of individuals with memory
problems.
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